{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T15:45:10Z","timestamp":1787327110816,"version":"build-2736575974"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T00:00:00Z","timestamp":1787270400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T00:00:00Z","timestamp":1787270400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"DOI":"10.1007\/s12094-026-04552-w","type":"journal-article","created":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T14:41:02Z","timestamp":1787323262000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Systemic and local dysregulation of the complement system in glioma: a comprehensive systematic review"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3651-4129","authenticated-orcid":false,"given":"Omar","family":"Alomari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tasneem","family":"Alomari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beyzanur","family":"G\u00fcney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Habiba","family":"Eyvazova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tesnim Soukaina","family":"Benamara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sondos","family":"Alomari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merzan","family":"Bing\u00f6l","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hatice","family":"Odabas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,21]]},"reference":[{"issue":"1","key":"4552_CR1","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/s11060-011-0738-7","volume":"107","author":"M Koshy","year":"2012","unstructured":"Koshy M, Villano JL, Dolecek TA, Howard A, Mahmood U, Chmura SJ. Improved survival time trends for glioblastoma using the SEER 17 population-based registries. J Neurooncol. 2012;107(1):207\u201312.","journal-title":"J Neurooncol"},{"issue":"21","key":"4552_CR2","doi-asserted-by":"publisher","first-page":"2683","DOI":"10.1101\/gad.1596707","volume":"21","author":"FB Furnari","year":"2007","unstructured":"Furnari FB, Fenton T, Bachoo RM, Mukasa A, Stommel JM, Stegh A, et al. Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev. 2007;21(21):2683\u2013710.","journal-title":"Genes Dev"},{"issue":"12 Suppl 2","key":"4552_CR3","doi-asserted-by":"publisher","first-page":"iv1","DOI":"10.1093\/neuonc\/noaa200","volume":"22","author":"QT Ostrom","year":"2020","unstructured":"Ostrom QT, Patil N, Cioffi G, Waite K, Kruchko C, Barnholtz-Sloan JS. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2013-2017. Neuro Oncol. 2020;22(12 Suppl 2):iv1\u201396. https:\/\/doi.org\/10.1093\/neuonc\/noaa200. (Erratum in: Neuro Oncol. 2022 Jul 1;24(7):1214. doi: 10.1093\/neuonc\/noaa269. PMID: 33123732; PMCID: PMC7596247.).","journal-title":"Neuro Oncol"},{"key":"4552_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2021.105780","volume":"171","author":"W Wu","year":"2021","unstructured":"Wu W, Klockow JL, Zhang M, Lafortune F, Chang E, Jin L. Glioblastoma multiforme (GBM): an overview of current therapies and mechanisms of resistance. Pharmacol Res. 2021;171:105780.","journal-title":"Pharmacol Res"},{"issue":"19","key":"4552_CR5","doi-asserted-by":"publisher","first-page":"6892","DOI":"10.1158\/0008-5472.CAN-04-1337","volume":"64","author":"H Ohgaki","year":"2004","unstructured":"Ohgaki H, Dessen P, Jourde B, Horstmann S, Nishikawa T, Di Patre PL, et al. Genetic pathways to glioblastoma: a population-based study. Cancer Res. 2004;64(19):6892\u20139.","journal-title":"Cancer Res"},{"issue":"19","key":"4552_CR6","doi-asserted-by":"publisher","first-page":"5671","DOI":"10.1158\/0008-5472.CAN-16-0144","volume":"76","author":"AL Chang","year":"2016","unstructured":"Chang AL, Miska J, Wainwright DA, Dey M, Rivetta CV, Yu D, et al. CCL2 produced by the glioma microenvironment is essential for the recruitment of regulatory t cells and myeloid-derived suppressor cells. Cancer Res. 2016;76(19):5671\u201382.","journal-title":"Cancer Res"},{"issue":"7","key":"4552_CR7","doi-asserted-by":"publisher","first-page":"494","DOI":"10.3390\/cells14070494","volume":"14","author":"J Tang","year":"2025","unstructured":"Tang J, Karbhari N, Campian JL. Therapeutic targets in glioblastoma: molecular pathways, emerging strategies, and future directions. Cells. 2025;14(7):494. https:\/\/doi.org\/10.3390\/cells14070494.","journal-title":"Cells"},{"issue":"1","key":"4552_CR8","doi-asserted-by":"publisher","DOI":"10.1186\/s40478-018-0591-4","volume":"6","author":"TAM Bouwens van der Vlis","year":"2018","unstructured":"Bouwens van der Vlis TAM, Kros JM, Mustafa DAM, van Wijck RTA, Ackermans L, van Hagen PM, et al. The complement system in glioblastoma multiforme. Acta Neuropathol Commun. 2018;6(1):91. https:\/\/doi.org\/10.1186\/s40478-018-0591-4. (PMID: 30208949; PMCID: PMC6134703.).","journal-title":"Acta Neuropathol Commun"},{"key":"4552_CR9","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/0-387-34134-X_6","volume":"586","author":"J Kohl","year":"2006","unstructured":"Kohl J. Self, non-self, and danger: a complementary view. Adv Exp Med Biol. 2006;586:71\u201394.","journal-title":"Adv Exp Med Biol"},{"issue":"4","key":"4552_CR10","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1093\/oxfordjournals.jbchem.a122524","volume":"104","author":"Y Sugita","year":"1988","unstructured":"Sugita Y, Nakano Y, Tomita M. Isolation from human erythrocytes of a new membrane protein which inhibits the formation of complement transmembrane channels. J Biochem. 1988;104(4):633\u20137.","journal-title":"J Biochem"},{"issue":"9","key":"4552_CR11","doi-asserted-by":"publisher","first-page":"3268","DOI":"10.1073\/pnas.73.9.3268","volume":"73","author":"JM Weiler","year":"1976","unstructured":"Weiler JM, Daha MR, Austen KF, Fearon DT. Control of the amplification convertase of complement by the plasma protein beta1H. Proc Natl Acad Sci U S A. 1976;73(9):3268\u201372.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"4552_CR12","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1084\/jem.146.1.22","volume":"146","author":"DT Fearon","year":"1977","unstructured":"Fearon DT, Austen KF. Activation of the alternative complement pathway with rabbit erythrocytes by circumvention of the regulatory action of endogenous control proteins. J Exp Med. 1977;146(1):22\u201333.","journal-title":"J Exp Med"},{"key":"4552_CR13","doi-asserted-by":"crossref","unstructured":"Yang, B., Lin, S. J., Ren, J. Y., Liu, T., Wang, Y. M., Li, C. M., ... & Liao, H. X. (2019). Molecular docking and molecular dynamics (MD) simulation of human anti-complement factor H (CFH) antibody Ab42 and CFH polypeptide. International Journal of Molecular Sciences, 20(10), 2568.","DOI":"10.3390\/ijms20102568"},{"key":"4552_CR14","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2020.1731135","volume":"9","author":"KI Smolag","year":"2020","unstructured":"Smolag KI, Mueni CM, Leandersson K, Jirstrom K, Hagerling C, Morgelin M, et al. Complement inhibitor factor H expressed by breast cancer cells differentiates CD14+ human monocytes into immunosuppressive macrophages. Oncoimmunology. 2020;9:1731135.","journal-title":"Oncoimmunology"},{"key":"4552_CR15","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1111\/j.1749-6632.1976.tb41656.x","volume":"276","author":"K Nishioka","year":"1976","unstructured":"Nishioka K, Kawamura K, Hirayama T, Kawashima T, Shimada K, Kogure M. The complement system in tumour immunity: significance of elevated levels of complement in tumour bearing hosts. Ann N Y Acad Sci. 1976;276:303\u201315.","journal-title":"Ann N Y Acad Sci"},{"key":"4552_CR16","unstructured":"Sakamoto, M., K. Nishioka: Studies on rat complement. II. Complement level in experimental tumour in rats. Japan. J. Exp. Med. 45 (1975) 191\u2013198."},{"key":"4552_CR17","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.754920","volume":"11","author":"XY Chen","year":"2022","unstructured":"Chen XY, Pan DL, Xu JH, et al. Serum inflammatory biomarkers contribute to the prognosis prediction in high-grade glioma. Front Oncol. 2022;11:754920. https:\/\/doi.org\/10.3389\/fonc.2021.754920.","journal-title":"Front Oncol"},{"issue":"1","key":"4552_CR18","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.canlet.2015.12.005","volume":"372","author":"HS Seol","year":"2016","unstructured":"Seol HS, Lee SE, Song JS, Rhee JK, Singh SR, Chang S, et al. Complement proteins C7 and CFH control the stemness of liver cancer cells via LSF-1. Cancer Lett. 2016;372(1):24\u201335. https:\/\/doi.org\/10.1016\/j.canlet.2015.12.005.","journal-title":"Cancer Lett"},{"issue":"12","key":"4552_CR19","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1038\/s41568-019-0210-0","volume":"19","author":"LT Roumenina","year":"2019","unstructured":"Roumenina LT, Daugan MV, Petitprez F, Saut\u00e8s-Fridman C, Fridman WH. Context-dependent roles of complement in cancer. Nat Rev Cancer. 2019;19(12):698\u2013715. https:\/\/doi.org\/10.1038\/s41568-019-0210-0. (Epub 2019 Oct 30 PMID: 31666715).","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"4552_CR20","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-024-01544-7","volume":"17","author":"H Lin","year":"2024","unstructured":"Lin H, Liu C, Hu A, Zhang D, Yang H, Mao Y. Understanding the immunosuppressive microenvironment of glioma: mechanistic insights and clinical perspectives. J Hematol Oncol. 2024;17(1):31. https:\/\/doi.org\/10.1186\/s13045-024-01544-7.","journal-title":"J Hematol Oncol"},{"key":"4552_CR21","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1003583","volume":"18","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. PLoS Med. 2021;18:e1003583.","journal-title":"PLoS Med"},{"key":"4552_CR22","volume-title":"Cochrane handbook for systematic reviews of interventions","author":"JPT Higgins","year":"2020","unstructured":"Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al. Cochrane handbook for systematic reviews of interventions. Hoboken, NJ: John Wiley & Sons; 2020."},{"key":"4552_CR23","doi-asserted-by":"publisher","unstructured":"Min, Saw Nay; Duangthip, Duangporn; Detsomboonrat, Palinee (2024). QUIN tool (risk of bias tool for assessing In vitro studies).. PLOS ONE. Dataset. https:\/\/doi.org\/10.1371\/journal.pone.0306367.t001","DOI":"10.1371\/journal.pone.0306367.t001"},{"key":"4552_CR24","unstructured":"National Heart, Lung and Blood Institute . (2019). Study quality assessment tools. Available at: https:\/\/www.nhlbi.nih.gov\/health-topics\/study-quality-assessment-tools"},{"issue":"1","key":"4552_CR25","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/BF01743288","volume":"7","author":"M Matsutani","year":"1984","unstructured":"Matsutani M, Suzuki T, Hori T, Terao H, Takakura K, Nishioka K. Cellular immunity and complement levels in hosts with brain tumours. Neurosurg Rev. 1984;7(1):29\u201335. https:\/\/doi.org\/10.1007\/BF01743288.","journal-title":"Neurosurg Rev"},{"issue":"11","key":"4552_CR26","doi-asserted-by":"publisher","first-page":"6075","DOI":"10.4049\/jimmunol.164.11.6075","volume":"164","author":"S Junnikkala","year":"2000","unstructured":"Junnikkala S, Jokiranta TS, Friese MA, Jarva H, Zipfel PF, Meri S. Exceptional resistance of human H2 glioblastoma cells to complement-mediated killing by expression and utilization of factor H and factor H-like protein 1. J Immunol. 2000;164(11):6075\u201381. https:\/\/doi.org\/10.4049\/jimmunol.164.11.6075.","journal-title":"J Immunol"},{"key":"4552_CR27","doi-asserted-by":"publisher","first-page":"5704","DOI":"10.12659\/MSM.910180","volume":"24","author":"A Bian","year":"2018","unstructured":"Bian A, Wang Y, Liu J, et al. Circular RNA complement factor H (CFH) promotes glioma progression by sponging miR-149 and regulating AKT1. Med Sci Monit. 2018;24:5704\u201312. https:\/\/doi.org\/10.12659\/MSM.910180.","journal-title":"Med Sci Monit"},{"issue":"5","key":"4552_CR28","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.imbio.2019.07.006","volume":"224","author":"S DeCordova","year":"2019","unstructured":"DeCordova S, Abdelgany A, Murugaiah V, et al. Secretion of functionally active complement factor H related protein 5 (FHR5) by primary tumour cells derived from glioblastoma multiforme patients. Immunobiology. 2019;224(5):625\u201331. https:\/\/doi.org\/10.1016\/j.imbio.2019.07.006.","journal-title":"Immunobiology"},{"issue":"23","key":"4552_CR29","doi-asserted-by":"publisher","first-page":"6514","DOI":"10.1158\/1078-0432.CCR-21-1392","volume":"27","author":"L Zhai","year":"2021","unstructured":"Zhai L, Bell A, Ladomersky E, et al. Tumor Cell IDO Enhances Immune Suppression and Decreases Survival Independent of Tryptophan Metabolism in Glioblastoma. Clin Cancer Res. 2021;27(23):6514\u201328. https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-1392.","journal-title":"Clin Cancer Res"},{"issue":"5","key":"4552_CR30","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1111\/ejn.15580","volume":"55","author":"S Guan","year":"2022","unstructured":"Guan S, Jian L, He Y, Su Y, Zhou L. Bioinformatic identification of differentially expressed genes regulated by DNA-methylation in glioblastoma. Eur J Neurosci. 2022;55(5):1278\u201390. https:\/\/doi.org\/10.1111\/ejn.15580.","journal-title":"Eur J Neurosci"},{"issue":"12","key":"4552_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-022-05514-0","volume":"13","author":"M Vedunova","year":"2022","unstructured":"Vedunova M, Turubanova V, Vershinina O, et al. DC vaccines loaded with glioma cells killed by photodynamic therapy induce Th17 anti-tumor immunity and provide a four-gene signature for glioma prognosis. Cell Death Dis. 2022;13(12):1062. https:\/\/doi.org\/10.1038\/s41419-022-05514-0.","journal-title":"Cell Death Dis"},{"issue":"1","key":"4552_CR32","doi-asserted-by":"publisher","DOI":"10.1007\/s12672-024-01520-0","volume":"15","author":"M Cao","year":"2024","unstructured":"Cao M, Zhang W, Chen J, Zhang Y. Identification of a coagulation-related gene signature for predicting prognosis in recurrent glioma. Discov Oncol. 2024;15(1):642. https:\/\/doi.org\/10.1007\/s12672-024-01520-0.","journal-title":"Discov Oncol"},{"issue":"1","key":"4552_CR33","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1158\/2326-6066.CIR-23-1092","volume":"13","author":"KI Smolag","year":"2025","unstructured":"Smolag KI, Olszowka J, Rosberg R, et al. Complement factor H is an ICOS ligand modulating Tregs in the glioma microenvironment. Cancer Immunol Res. 2025;13(1):122\u201338. https:\/\/doi.org\/10.1158\/2326-6066.CIR-23-1092.","journal-title":"Cancer Immunol Res"},{"issue":"4","key":"4552_CR34","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.4049\/jimmunol.149.4.1381","volume":"149","author":"P Gasque","year":"1992","unstructured":"Gasque P, Julen N, Ischenko AM, et al. Expression of complement components of the alternative pathway by glioma cell lines. J Immunol. 1992;149(4):1381\u20137.","journal-title":"J Immunol"},{"key":"4552_CR35","doi-asserted-by":"publisher","unstructured":"Gahoi N, Malhotra D, Moiyadi A, Varma SG, Gandhi MN, Srivastava S. Multi-Pronged Proteomic Analysis to Study the Glioma Pathobiology using Cerebrospinal Fluid Samples. Proteomics Clin Appl. 2018;12(2):https:\/\/doi.org\/10.1002\/prca.201870013. 10.1002\/prca.201870013","DOI":"10.1002\/prca.201870013"},{"key":"4552_CR36","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2020.615970","volume":"8","author":"X Cai","year":"2021","unstructured":"Cai X, Qiu W, Qian M, Feng S, Peng C, Zhang J, et al. A Candidate Prognostic Biomarker Complement Factor I Promotes Malignant Progression in Glioma. Front Cell Dev Biol. 2021;8:615970. https:\/\/doi.org\/10.3389\/fcell.2020.615970.","journal-title":"Front Cell Dev Biol"},{"issue":"100","key":"4552_CR37","doi-asserted-by":"publisher","first-page":"37421","DOI":"10.18632\/oncotarget.26456","volume":"9","author":"K F\u00f6rnvik","year":"2018","unstructured":"F\u00f6rnvik K, Ahlstedt J, Osther K, Salford LG, Redebrandt HN. Anti-C1-inactivator treatment of glioblastoma. Oncotarget. 2018;9(100):37421\u20138. https:\/\/doi.org\/10.18632\/oncotarget.26456.","journal-title":"Oncotarget"},{"issue":"9","key":"4552_CR38","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0183086","volume":"12","author":"K F\u00f6rnvik","year":"2017","unstructured":"F\u00f6rnvik K, Maddahi A, Persson O, Osther K, Salford LG, Nittby Redebrandt H. C1-inactivator is upregulated in glioblastoma. PLoS ONE. 2017;12(9):e0183086. https:\/\/doi.org\/10.1371\/journal.pone.0183086.","journal-title":"PLoS ONE"},{"issue":"1","key":"4552_CR39","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-023-10583-1","volume":"23","author":"E Liljedahl","year":"2023","unstructured":"Liljedahl E, Konradsson E, Gustafsson E, et al. Combined anti-C1-INH and radiotherapy against glioblastoma. BMC Cancer. 2023;23(1):106. https:\/\/doi.org\/10.1186\/s12885-023-10583-1.","journal-title":"BMC Cancer"},{"issue":"1-2","key":"4552_CR40","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/s0169-328x(02)00404-7","volume":"106","author":"M Nakagawa","year":"2002","unstructured":"Nakagawa M, Nakashima S, Banno Y, et al. Increased expression and secretion of r-Gsp protein, rat counterpart of complement C1s precursor, during cyclic AMP-induced differentiation in rat C6 glioma cells. Brain Res Mol Brain Res. 2002;106(1\u20132):12\u201321. https:\/\/doi.org\/10.1016\/s0169-328x(02)00404-7.","journal-title":"Brain Res Mol Brain Res"},{"key":"4552_CR41","doi-asserted-by":"publisher","first-page":"7981609","DOI":"10.1155\/2020\/7981609","volume":"2020","author":"GR Naro","year":"2020","unstructured":"Naro GR, Noverati N, Craig T. The Role of C1-Esterase Inhibitors in the Management of Vasogenic Edema in Glioblastoma. Case Rep Med. 2020;2020:7981609. https:\/\/doi.org\/10.1155\/2020\/7981609.","journal-title":"Case Rep Med"},{"issue":"4","key":"4552_CR42","first-page":"1139","volume":"148","author":"A M\u00e4enp\u00e4\u00e4","year":"1996","unstructured":"M\u00e4enp\u00e4\u00e4 A, Junnikkala S, Hakulinen J, Timonen T, Meri S. Expression of complement membrane regulators membrane cofactor protein (CD46), decay accelerating factor (CD55), and protectin (CD59) in human malignant gliomas. Am J Pathol. 1996;148(4):1139\u201352.","journal-title":"Am J Pathol"},{"issue":"17","key":"4552_CR43","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241713413","volume":"24","author":"X Ren","year":"2023","unstructured":"Ren X, Chang C, Qi T, Yang P, Wang Y, Zhou X, et al. Clusterin is a prognostic biomarker of lower-grade gliomas and is associated with immune cell infiltration. Int J Mol Sci. 2023;24(17):13413. https:\/\/doi.org\/10.3390\/ijms241713413.","journal-title":"Int J Mol Sci"},{"key":"4552_CR44","doi-asserted-by":"publisher","DOI":"10.1186\/s13287-025-04247-z","volume":"16","author":"J Wen","year":"2025","unstructured":"Wen J, Wu X, Shu Z, et al. Clusterin-mediated polarization of M2 macrophages: a mechanism of temozolomide resistance in glioblastoma stem cells. Stem Cell Res Ther. 2025;16:146. https:\/\/doi.org\/10.1186\/s13287-025-04247-z.","journal-title":"Stem Cell Res Ther"},{"issue":"6","key":"4552_CR45","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics17060679","volume":"17","author":"P Sultana","year":"2025","unstructured":"Sultana P, Novotny J. Curcumin-induced apoptotic cell death in human glioma cells is enhanced by clusterin deficiency. Pharmaceutics. 2025;17(6):679. https:\/\/doi.org\/10.3390\/pharmaceutics17060679.","journal-title":"Pharmaceutics"},{"issue":"12 Suppl 2","key":"4552_CR46","doi-asserted-by":"publisher","first-page":"iii1","DOI":"10.1093\/neuonc\/noab200","volume":"23","author":"QT Ostrom","year":"2021","unstructured":"Ostrom QT, Cioffi G, Waite K, Kruchko C, Barnholtz-Sloan JS. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2014-2018. Neuro Oncol. 2021;23(12 Suppl 2):iii1\u2013105. https:\/\/doi.org\/10.1093\/neuonc\/noab200.","journal-title":"Neuro Oncol"},{"key":"4552_CR47","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-024-00516-y","volume":"10","author":"M Weller","year":"2024","unstructured":"Weller M, Wen PY, Chang SM, et al. Glioma. Nat Rev Dis Primers. 2024;10:33. https:\/\/doi.org\/10.1038\/s41572-024-00516-y.","journal-title":"Nat Rev Dis Primers"},{"issue":"1","key":"4552_CR48","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1186\/s40364-025-00863-2","volume":"13","author":"J Cvitkovi\u0107","year":"2025","unstructured":"Cvitkovi\u0107 J, Tan WL, Jiang T, Zhao Z. Glioma tumor microenvironment and immunotherapy: past, present, and future. Biomark Res. 2025;13(1):150. https:\/\/doi.org\/10.1186\/s40364-025-00863-2.","journal-title":"Biomark Res"},{"key":"4552_CR49","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1682322","volume":"16","author":"L Xu","year":"2025","unstructured":"Xu L, Chen S, Fu Y, et al. Neuro-immune-tumor axis in gliomas: a review of mechanisms, models, and translational opportunities. Front Immunol. 2025;16:1682322. https:\/\/doi.org\/10.3389\/fimmu.2025.1682322.","journal-title":"Front Immunol"},{"issue":"3","key":"4552_CR50","doi-asserted-by":"publisher","DOI":"10.1016\/j.bvth.2024.100012","volume":"1","author":"T Stein","year":"2024","unstructured":"Stein T, Bitsina C, Seiler M, Schmugge M, Franzoso FD. Clusterin can mediate apoptosis-induced molecular mechanisms in immune thrombocytopenia. Blood Vessels Thromb Hemost. 2024;1(3):100012. https:\/\/doi.org\/10.1016\/j.bvth.2024.100012.","journal-title":"Blood Vessels Thromb Hemost"},{"issue":"18","key":"4552_CR51","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1016\/j.molimm.2003.12.002","volume":"40","author":"AM Blom","year":"2004","unstructured":"Blom AM, Villoutreix BO, Dahlb\u00e4ck B. Complement inhibitor C4b-binding protein-friend or foe in the innate immune system? Mol Immunol. 2004;40(18):1333\u201346. https:\/\/doi.org\/10.1016\/j.molimm.2003.12.002.","journal-title":"Mol Immunol"},{"key":"4552_CR52","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.smim.2018.02.003","volume":"37","author":"M Kolev","year":"2018","unstructured":"Kolev M, Markiewski MM. Targeting complement-mediated immunoregulation for cancer immunotherapy. Semin Immunol. 2018;37:85\u201397. https:\/\/doi.org\/10.1016\/j.smim.2018.02.003.","journal-title":"Semin Immunol"},{"issue":"12","key":"4552_CR53","doi-asserted-by":"publisher","first-page":"2184","DOI":"10.1016\/j.cell.2022.04.038","volume":"185","author":"FS Varn","year":"2022","unstructured":"Varn FS, Johnson KC, Martinek J, Huse JT, Nasrallah MP, Wesseling P, et al. Glioma progression is shaped by genetic evolution and microenvironment interactions. Cell. 2022;185(12):2184-2199.e16. https:\/\/doi.org\/10.1016\/j.cell.2022.04.038.","journal-title":"Cell"},{"issue":"1","key":"4552_CR54","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/s41568-019-0205-x","volume":"20","author":"CD Arvanitis","year":"2020","unstructured":"Arvanitis CD, Ferraro GB, Jain RK. The blood-brain barrier and blood-tumour barrier in brain tumours and metastases. Nat Rev Cancer. 2020;20(1):26\u201341. https:\/\/doi.org\/10.1038\/s41568-019-0205-x.","journal-title":"Nat Rev Cancer"},{"issue":"2","key":"4552_CR55","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1007\/s13311-017-0520-4","volume":"14","author":"AM Mehta","year":"2017","unstructured":"Mehta AM, Sonabend AM, Bruce JN. Convection-enhanced delivery. Neurotherapeutics. 2017;14(2):358\u201371. https:\/\/doi.org\/10.1007\/s13311-017-0520-4.","journal-title":"Neurotherapeutics"},{"issue":"15","key":"4552_CR56","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17152550","volume":"17","author":"O Alomari","year":"2025","unstructured":"Alomari O, Eyvazova H, G\u00fcney B, et al. Oncolytic therapies for glioblastoma: advances, challenges, and future perspectives. Cancers (Basel). 2025;17(15):2550. https:\/\/doi.org\/10.3390\/cancers17152550.","journal-title":"Cancers (Basel)"},{"issue":"5","key":"4552_CR57","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0349101","volume":"21","author":"L Blomberg","year":"2026","unstructured":"Blomberg L, Raba L, Bengzon J, Osther K, Nittby Redebrandt H. Overexpression of key complement regulators in glioblastoma. PLoS ONE. 2026;21(5):e0349101. https:\/\/doi.org\/10.1371\/journal.pone.0349101.","journal-title":"PLoS ONE"},{"issue":"9","key":"4552_CR58","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15092647","volume":"15","author":"F Ah-Pine","year":"2023","unstructured":"Ah-Pine F, Malaterre-Septembre A, Bedoui Y, Khettab M, Neal JW, Freppel S, et al. Complement activation and up-regulated expression of anaphylatoxin C3a\/C3aR in glioblastoma: deciphering the links with TGF-\u03b2 and VEGF. Cancers (Basel). 2023;15(9):2647. https:\/\/doi.org\/10.3390\/cancers15092647.","journal-title":"Cancers (Basel)"},{"key":"4552_CR59","doi-asserted-by":"publisher","first-page":"2175","DOI":"10.1038\/s41467-025-57104-7","volume":"16","author":"R Rosberg","year":"2025","unstructured":"Rosberg R, Smolag KI, Sj\u00f6lund J, Johansson E, Bergelin C, Wahld\u00e9n J, et al. Hypoxia-induced complement component 3 promotes aggressive tumor growth in the glioblastoma microenvironment. Nat Commun. 2025;16:2175. https:\/\/doi.org\/10.1038\/s41467-025-57104-7.","journal-title":"Nat Commun"},{"key":"4552_CR60","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2024.113236","volume":"141","author":"L Gao","year":"2024","unstructured":"Gao L, Jing X, Hua Q, Li Z, Lei P, Song P, et al. Complement C1S is a potential prognostic biomarker and associated with M2 macrophage infiltration in gliomas: From bioinformatics to comprehensive experimental validation. Int Immunopharmacol. 2024;141:113236. https:\/\/doi.org\/10.1016\/j.intimp.2024.113236.","journal-title":"Int Immunopharmacol"},{"key":"4552_CR61","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2021.675498","volume":"12","author":"L Cen","year":"2021","unstructured":"Cen L, Liu R, Liu W, Li Q, Cui H. Competing endogenous RNA networks in glioma. Front Genet. 2021;12:675498. https:\/\/doi.org\/10.3389\/fgene.2021.675498.","journal-title":"Front Genet"},{"issue":"14","key":"4552_CR62","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13143524","volume":"13","author":"L Bitar","year":"2021","unstructured":"Bitar L, Schumann U, K\u00f6nig R, Zipp F, Schmidt MHH. Targeting immune modulators in glioma while avoiding autoimmune conditions. Cancers (Basel). 2021;13(14):3524. https:\/\/doi.org\/10.3390\/cancers13143524.","journal-title":"Cancers (Basel)"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-026-04552-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-026-04552-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-026-04552-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T14:41:05Z","timestamp":1787323265000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-026-04552-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,21]]},"references-count":62,"alternative-id":["4552"],"URL":"https:\/\/doi.org\/10.1007\/s12094-026-04552-w","relation":{},"ISSN":["1699-3055"],"issn-type":[{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,21]]},"assertion":[{"value":"16 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflicts of interest in preparing this paper.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}